アストラでもええからワクチンハヨハヨ！

アストラゼネカ・オックスフォードのワクチンはファイザー、モデルナのそれより劣る、という意見がありますが、そういうわけではありません。直接比較がないものを比較するのは困難です。理由はここ。　https://t.co/IFtfnkMYS5

— 岩田健太郎 Kentaro Iwata (@georgebest1969) February 22, 2021

 There is no sign that the South Africa variant will become dominant in the UK, the government's deputy chief medical officer, Jonathan Van Tam, has said. The "immediate threat" is from the UK or Kent variant and there is "plenty of evidence" the vaccine is effective against that, Prof Van Tam added.

Research has shown it is highly effective. No one given the vaccine in trials developed severe Covid or needed hospital treatment.

No-one who received the Oxford vaccine was hospitalised or became seriously ill due to Covid.

Covid variants: What are they and will vaccines work?’

By Michelle Roberts

Health editor, BBC News online

 

Early results suggest the Pfizer vaccine protects against the new variants, but is slightly less effective.

Two new coronavirus vaccines that could be approved soon - one from Novavax and another from Janssen - appear to offer some protection too.

Data from the Oxford-AstraZeneca vaccine team suggests it protects just as well against the new UK variant. It offers less protection against the South Africa variant - although it should still protect against severe illness.

Early results from Moderna suggest its vaccine is effective against the South Africa variant, although the immune response may not be as strong or long-lasting.

アストラは南ア種に弱いが・・・・重症にはならないようにしてくれるみたいだし・・・水際強化して南ア種の拡散、流行を防止できれば・・・・・それで十分でしょ。 

スコットランドのデータでは、高齢者でもアストラのワクチンのコロナの重症化を抑える効果はかなり高いらしい。Scotland Covid vaccination drive linked to big drop in hospital admissions https://t.co/XNn3rVibTn

— kazukazu88 (@kazukazu881) February 22, 2021

更新 

 The study suggested that both vaccines were working well, said the researchers. The study was not set up to look at any differences between the two. The Pfizer/BioNTech was available first so there is more data, but the Oxford/AstraZeneca was mostly used in the older age group. 

 The Oxford/AstraZeneca vaccine appears to have performed very well in older people. Only two people given that vaccine were admitted to hospital in the study. There were more hospital admissions in those given the Pfizer vaccine, but among more people immunised. Even so, the very good Oxford vaccine results could cause a rethink in those countries that have decided not to allow it to be used in people over the age of 65 because of a shortage of trial data.